INT181790

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.72
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 14
Disease Relevance 11.73
Pain Relevance 0.56

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (FLT4) plasma membrane (FLT4) nucleus (FLT4)
cytoplasm (FLT4)
Anatomy Link Frequency
lymphatic vessels 3
plasma 2
stems 2
endothelium 1
FLT4 (Homo sapiens)
Pain Link Frequency Relevance Heat
COX2 1 93.60 High High
cytokine 156 93.48 High High
Inflammation 69 78.68 Quite High
Inflammatory stimuli 8 36.28 Quite Low
Pain 24 5.00 Very Low Very Low Very Low
Paracetamol 20 5.00 Very Low Very Low Very Low
headache 20 5.00 Very Low Very Low Very Low
drug abuse 10 5.00 Very Low Very Low Very Low
alcohol 10 5.00 Very Low Very Low Very Low
tolerance 7 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Infection 182 99.84 Very High Very High Very High
Inflammatory Breast Neoplasms 134 99.56 Very High Very High Very High
Targeted Disruption 42 99.50 Very High Very High Very High
Lymphedema 868 99.32 Very High Very High Very High
Disease Progression 12 99.20 Very High Very High Very High
Lymphatic Filariasis 280 98.28 Very High Very High Very High
Cancer 127 97.60 Very High Very High Very High
Disease 207 97.16 Very High Very High Very High
Helminth Infection 650 96.56 Very High Very High Very High
Peripheral Arterial Disease 1 83.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Additional evidence for the role of VEGF-C/VEGF-D/VEGFR-3 in the pathogenesis of lymphatic dilation and lymphedema stems from experimental studies in transgenic mice with skin specific overexpression of soluble VEGFR-3 (sVEGFR-3) using a keratin 14 transgenic promoter [36].
Gene_expression (overexpression) of VEGFR-3 in stems associated with targeted disruption and lymphedema
1) Confidence 0.72 Published 2006 Journal PLoS Pathogens Section Body Doc Link PMC1564427 Disease Relevance 0.76 Pain Relevance 0.05
Importantly, the reduction of the VEGF-C/sVEGFR-3 preceded the amelioration of the dilated lymphatic vessels and LE.
Gene_expression (reduction) of VEGFR-3 in lymphatic vessels associated with lymphedema
2) Confidence 0.65 Published 2009 Journal Parasite Immunology Section Body Doc Link PMC2784903 Disease Relevance 0.75 Pain Relevance 0
Here, we have provided circumstantial evidence for both, in a series of events: the lymphatic dilation may be partly caused by overexpression of VEGF-C/sVEGFR-3 produced by the endothelial cells of the lymphatic vessels of the host in response to products of the adult worm that are reduced by doxycycline.
Gene_expression (produced) of sVEGFR-3 in lymphatic vessels associated with helminth infection
3) Confidence 0.63 Published 2006 Journal PLoS Pathogens Section Body Doc Link PMC1564427 Disease Relevance 0.77 Pain Relevance 0
There was also a positive association between levels of VEGF-C and antigenemia (r = 0.434, p < 0.0001) and between levels of sVEGFR-3 and antigenemia (r = 0.367, p = 0.0065), but no associations between microfilaremia and levels of VEGF-C (p = 0.8864) and sVEGFR-3 (p = 0.7720) were found.


Gene_expression (levels) of sVEGFR-3
4) Confidence 0.63 Published 2006 Journal PLoS Pathogens Section Body Doc Link PMC1564427 Disease Relevance 0.35 Pain Relevance 0
Additional evidence for the role of VEGF-C/VEGF-D/VEGFR-3 in the pathogenesis of lymphatic dilation and lymphedema stems from experimental studies in transgenic mice with skin specific overexpression of soluble VEGFR-3 (sVEGFR-3) using a keratin 14 transgenic promoter [36].
Gene_expression (overexpression) of sVEGFR-3 in stems associated with targeted disruption and lymphedema
5) Confidence 0.63 Published 2006 Journal PLoS Pathogens Section Body Doc Link PMC1564427 Disease Relevance 0.76 Pain Relevance 0.06
Here, we have provided circumstantial evidence for both, in a series of events: the lymphatic dilation may be partly caused by overexpression of VEGF-C/sVEGFR-3 produced by the endothelial cells of the lymphatic vessels of the host in response to products of the adult worm that are reduced by doxycycline.
Gene_expression (overexpression) of sVEGFR-3 in lymphatic vessels associated with helminth infection
6) Confidence 0.63 Published 2006 Journal PLoS Pathogens Section Body Doc Link PMC1564427 Disease Relevance 0.77 Pain Relevance 0
Although both microfilaremic and lymphedema patients had elevated VEGF-C and sVEGFR-3 levels, those of sVEGFR-3 were yet significantly higher in lymphedema patients compared to non-lymphedema patients that are microfilaremic (p = 0.0024, Figure 4).
Gene_expression (levels) of sVEGFR-3 associated with lymphedema
7) Confidence 0.55 Published 2006 Journal PLoS Pathogens Section Body Doc Link PMC1564427 Disease Relevance 1.15 Pain Relevance 0.08
This could be an indication that plasma levels of VEGF-C/sVEGFR-3 may correlate with disease progression in LF leading to lymphatic dilation and lymphedema development and hence, might be developed as prognostic indicators of an increased risk of LF pathology before it actually becomes manifest.
Gene_expression (levels) of sVEGFR-3 in plasma associated with lymphatic filariasis, lymphedema and disease progression
8) Confidence 0.55 Published 2006 Journal PLoS Pathogens Section Body Doc Link PMC1564427 Disease Relevance 1.18 Pain Relevance 0.07
There was also a positive association between levels of VEGF-C and antigenemia (r = 0.434, p < 0.0001) and between levels of sVEGFR-3 and antigenemia (r = 0.367, p = 0.0065), but no associations between microfilaremia and levels of VEGF-C (p = 0.8864) and sVEGFR-3 (p = 0.7720) were found.


Gene_expression (found) of sVEGFR-3
9) Confidence 0.55 Published 2006 Journal PLoS Pathogens Section Body Doc Link PMC1564427 Disease Relevance 0.35 Pain Relevance 0
For this, a prospective study is needed that would screen VEGF-C and sVEGFR-3 levels in children and young adults, and monitor development of pathology such as lymphedema.
Gene_expression (levels) of sVEGFR-3 associated with lymphedema
10) Confidence 0.55 Published 2006 Journal PLoS Pathogens Section Body Doc Link PMC1564427 Disease Relevance 1.16 Pain Relevance 0.03
Interestingly, the plasma levels of sVEGFR-3 were significantly higher in lymphedema patients than in microfilaremic patients without lymphedema (p = 0.0024, Figure 4).
Gene_expression (levels) of sVEGFR-3 in plasma associated with lymphedema
11) Confidence 0.49 Published 2006 Journal PLoS Pathogens Section Body Doc Link PMC1564427 Disease Relevance 0.62 Pain Relevance 0
However, other major angiogenic genes (VEGF2, VEGF3, VEGF4, VEGFR1, VEGFR2, and VEGFR3) had similar expression levels in IBC and non-IBC [31].


Gene_expression (expression) of VEGFR3 associated with inflammatory breast neoplasms
12) Confidence 0.44 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1064141 Disease Relevance 1.45 Pain Relevance 0.05
VEGFR-3 is normally expressed in the lymphatic endothelium and is also over-expressed in tumor cells.
Gene_expression (expressed) of VEGFR-3 in endothelium associated with cancer
13) Confidence 0.38 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 0.85 Pain Relevance 0.03
Evidence was provided in a recent study, which showed that increased levels of VEGF-C were associated with infection, while VEGFR3 levels were yet significantly higher in LE than in other conditions of LF infection (11).
Gene_expression (levels) of VEGFR3 associated with lymphatic filariasis, lymphedema and infection
14) Confidence 0.07 Published 2009 Journal Parasite Immunology Section Body Doc Link PMC2784903 Disease Relevance 0.81 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox